Molecular Pharming Solution was founded with the conviction that the future of biologics would not be confined to the limitations of existing manufacturing systems — but expanded through new molecular capabilities that had long remained out of reach. Our path was never about replacing what came before, but about unlocking entirely new therapeutic formats through molecular pharming with Nicotiana benthamiana.

In the beginning, there were doubts — not about the science, but about whether a plant-based system could ever achieve true pharmaceutical precision and consistency. That question became our standard. We built our platform not as an experiment, but as a rigorously engineered system capable of meeting international expectations for quality, safety, and reproducibility.

N. benthamiana offers what conventional platforms were never designed for: the ability to rapidly develop, adapt, and manufacture complex protein therapeutics that evolve as medicine evolves — from next-generation biologics to potentially patient-personalized treatments. It is a system that expands what is possible, rather than competing with what already exists.

Our responsibility extends beyond technical innovation. Southeast Asia — long underserved in the global biotechnology landscape — deserves infrastructure that not only receives innovation, but contributes to it. For us, this is not merely a regional ambition, but a global obligation.

The foundation we are building is not temporary. It is designed to serve the next era of biologics — one defined by speed, adaptability, and scientific precision.

We are only at the beginning.

Jompong Champaiboon
Founder & CEO
Molecular Pharming Solution